Ocuphire Announces Appointment of Jay S. Pepose, M.D.,
Dr. Pepose is Recognized as an Esteemed Key Opinion Leader in Ophthalmology with Nearly 40 Years of Experience as a Leading Clinical Researcher and...
Stay updated with breaking news from Mina Sooch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Pepose is Recognized as an Esteemed Key Opinion Leader in Ophthalmology with Nearly 40 Years of Experience as a Leading Clinical Researcher and...
Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient ...
Webcast examines post-pandemic M&A outlook Crain's Detroit Business Laura Marcero. The pandemic reshaped mergers and acquisitions in 2020, but it didn't halt them. Crain's will take a look back at the deals of 2020 and what to expect in 2021 in M&A trends in a webcast at 3:30 p.m. March 10. Senior reporter Dustin Walsh will host a series of conversations with guests including: Mina Sooch, CEO and co-founder, Ocuphire Pharma Inc. Greg Lehmkuhl, president and CEO, Lineage Logistics Rajesh U. Kothari, CFA managing director, Cascade Partners LLC Laura Marcero, managing director, Huron Consulting ...
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances January 05, 2021 07:00 ET | Source: Ocuphire Pharma Ocuphire Pharma Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced the initiation of patient recruit...